Definitive Contract HHSN261201000130C
Ended Awarded Last action
- Contract number
- HHSN261201000130C
- Awardee
-
Stemina Biomarker Discovery, Inc. UEI H68RXEVTQCG5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $999,936
Award facts
- Opportunity
-
- N44CO0900315 Solicitation number
- Contract value 100% obligated
- $999,936.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Madison, WI 53719, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $999,936 |
About this award
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to Stemina Biomarker Discovery, Inc., a for-profit organization. The contract, valued at $999,936.00, is a definitive, cost-plus-fixed-fee contract set aside for small businesses.
The contract involves services related to Stemina's DevTox QuickPredict assay, a human pluripotent stem cell-based assay that uses a biomarker ratio to predict developmental toxicity potential. Through this contract, Stemina is providing these services as a subcontractor to the prime contractor, Battelle Memorial Institute. The goal is to conduct analytical method validation and reliability studies to evaluate the assay's repeatability, reproducibility, and relevance for predicting developmental toxicity, with the aim of qualifying the assay through the FDA's Biomarker Qualification Program. This could reduce animal testing and provide a more human-relevant approach to assessing developmental toxicity safety, ultimately improving drug safety and reducing birth defects.
Quick answers
Who was awarded contract HHSN261201000130C?
HHSN261201000130C was awarded to Stemina Biomarker Discovery, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2010.
How much is contract HHSN261201000130C worth?
The government has obligated $999,936 on HHSN261201000130C.
Was contract HHSN261201000130C competed?
The extent of competition for HHSN261201000130C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award